Spondyloarthritis & psoriatic arthritis
Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial
Authors' conclusion
Our results revealed that FIL treatment rapidly downregulates inflammatory and immune pathways associated with PsA disease activity corresponding to clinical improvement in PsA.
Study context
- Population
- Patients with active psoriatic arthritis (PsA) enrolled in the phase II EQUATOR trial
- Participants
- 121 patients
- Outcome
- Biomarkers and pathways associated with baseline disease state and FIL treatment
Methodological detailssecondary analysis of the phase II EQUATOR trial, linear mixed effects models for repeated measures, mediation analysis, structural equation modelling
- Secondary analysis of the phase II EQUATOR trial
- Linear mixed effects models for repeated measures
- Mediation analysis
- Structural equation modelling
Main finding
As reported in the abstract
- Baseline: inflammation markers significantly associated with multiple PsA clinical metrics, except Psoriasis Area and Severity Index (PASI), which corresponded to Th17 markers
- Filgotinib (FIL): sustained transcriptional inhibition of immune genes and pathways
- FIL: sustained increase in B-cell fraction and mature B-cells in circulation; transient effect on other cell fractions
- Mediation: changes in B cells, systemic inflammatory cytokines and neutrophils at week 4 associated with changes in clinical metrics at week 16
- Structural equation modelling (SEM): FIL improved PASI through reduction of IL-23 p19 and IL-12 p40 proteins
Original publication
Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial. RMD Open. Published 9 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →